In a study by Xiao et al., HR+ BCs were correlated with the risk of bone metastasis, HER2+ subtypes were significantly associated with higher rates of liver, brain, and lung metastasis, and triple-negative tumors had a higher rate of brain metastasis but a significantly lower rate of bone metastasis [31]. The gene discussed is ERBB2; the disease is bone metastasis.